Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Regulatory Filings
2026-06-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 97% confidence The document is a report of an executive/major shareholder’s specific securities ownership and transaction (“임원ㆍ주요주주 특정증권등 소유상황보고서”), detailing share counts before and after insider trades. This matches the “Director’s Dealing” category, which covers personal share transactions by company directors and executives.
2026-06-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 97% confidence The document is a Korean regulatory filing titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” which translates to an executive and major shareholder report of ownership and changes in securities holdings. It is submitted to the Financial Services Commission and Korea Exchange, listing an officer’s name, share count, percentage, and detailed acquisition/disposal information. This clearly falls under insider share transactions and holdings disclosures. Therefore, it should be classified as Director’s Dealing (DIRS).
2026-06-01 Korean
기업지배구조보고서공시
Governance Information Classification · 95% confidence The document is titled “기업지배구조보고서 신고서” and contains detailed management and board governance policies, key governance indicators, board composition, shareholder meeting procedures, and internal control policies. It is not an earnings release, annual report, proxy, or certification notice, but a full corporate governance report detailing internal rules, board structure, and governance practices. This matches the Governance Information category (CGR).
2026-05-29 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 97% confidence The document is a ‘최대주주등소유주식변동신고서’, which in Korean capital markets is the mandatory filing to notify changes in major shareholders’ ownership percentages. It details share counts before and after the change, individual transactions, and aggregate ownership of the controlling family group. This matches our category for major shareholding notifications (threshold-crossing ownership changes).
2026-05-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean-language filing titled “임원·주요주주 특정증권등 소유상황보고서” (Report on Securities Ownership of Officer/Major Shareholder). It details the holdings before and after transactions, discloses purchase on the market, and is submitted to the Securities Commission and Korea Exchange—clearly an insider trading/ownership disclosure by a company executive. This matches the Director’s Dealing category (insider trades).
2026-05-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.